Zobrazeno 1 - 10
of 63
pro vyhledávání: '"Nikos Fersis"'
Autor:
Carolin C. Hack MD, Peter A. Fasching MD, Tanja Fehm MD, Johann de Waal MD, Mahdi Rezai MD, Bernd Baier MD, Gerold Baake MD, Hans-Christian Kolberg MD, Martin Guggenberger MD, Mathias Warm MD, Nadia Harbeck MD, Rachel Wuerstlein MD, Jörg-Uwe Deuker MD, Peter Dall MD, Barbara Richter MD, Grischa Wachsmann MD, Cosima Brucker MD, Jan W. Siebers MD, Nikos Fersis MD, Thomas Kuhn MD, Christopher Wolf MD, Hans-Walter Vollert MD, Georg-Peter Breitbach MD, Wolfgang Janni MD, Robert Landthaler MD, Andreas Kohls MD, Daniela Rezek MD, Thomas Noesslet MD, Gunnar Fischer MD, Stefan Henschen MD, Thomas Praetz MD, Volker Heyl MD, Thorsten Kühn MD, Thomas Krauss MD, Christoph Thomssen MD, Andre Hohn MD, Hans Tesch MD, Christoph Mundhenke MD, Alexander Hein MD, Claudia Rauh MD, Christian M. Bayer MD, Adib Jacob, Katja Schmidt PhD, Erik Belleville PhD, Peyman Hadji MD, Sara Y. Brucker MD, Diethelm Wallwiener MD, Sherko Kümmel MD, Matthias W. Beckmann MD, Daniela Paepke MD
Publikováno v:
Integrative Cancer Therapies, Vol 16 (2017)
Background . Breast cancer patients often use complementary and alternative medicine, but few prospectively collected data on the topic are available specifically for postmenopausal breast cancer patients. A large prospective study was therefore cond
Externí odkaz:
https://doaj.org/article/d2a81d21043643fba118f1259ec81715
Publikováno v:
Der Gynäkologe. 52:354-359
Mehr als zwei Drittel der neu diagnostizierten Brustkrebserkrankungen sind hormonabhangige Tumoren. Als Standard bei pramenopausalen Patientinnen galt lange die 5‑jahrige adjuvante Therapie mit Tamoxifen und bei postmenopausalen Patientinnen mit ei
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0e7d71d5dd9e0896d487f2af510a373a
https://doi.org/10.1007/s00129-019-4426-6
https://doi.org/10.1007/s00129-019-4426-6
Autor:
Hans-Christian Kolberg, Sara Y. Brucker, Diethelm Wallwiener, Markus Wallwiener, Peyman Hadji, Erik Belleville, Carsten Hielscher, Bernhard Volz, Pauline Wimberger, Christoph Thomssen, Diana Lüftner, Michael Untch, Wolfgang Janni, Johannes Ettl, Hans Tesch, Naiba Nabieva, Judith Schwitulla, Jens Huober, Peter A. Fasching, Wolfgang Abenhardt, Andreas Schneeweiss, Matthias Geberth, Michael P. Lux, Volkmar Müller, Florin-Andrei Taran, Christian M. Kurbacher, Andreas D. Hartkopf, Tanja Fehm, Matthias W. Beckmann, Rachel Wuerstlein, Friedrich Overkamp, Lothar Häberle, Nikos Fersis
Publikováno v:
The Breast. 37:42-51
Purpose This study describes comprehensive data from a breast cancer registry concerning the use of endocrine treatment (ET) and chemotherapy in the first, second and higher therapy lines in hormone receptor (HR) positive, HER2 negative metastatic br
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04e357d459577e9ac0652f090e1913d7
https://doi.org/10.1016/j.breast.2017.10.002
https://doi.org/10.1016/j.breast.2017.10.002
Autor:
Sara Y. Brucker, C Brucker, Katja Schmidt, J. de Waal, V. Heyl, T. Praetz, P. Hadji, G. Wachsmann, Daniela Rezek, Peter A. Fasching, A. Jacob, J.-U. Deuker, Christian M. Bayer, Peter Dall, M Warm, G. Baake, Thomas Krauss, T Noesselt, Rachel Wuerstlein, Wolfgang Janni, Hans Tesch, Naiba Nabieva, G. Fischer, C. Wolf, M. Guggenberger, A. Hohn, M. W. Beckmann, G. P. Breitbach, Nadia Harbeck, Hans-Christian Kolberg, Barbara Richter, H.-W. Vollert, A. Kohls, Erik Belleville, Alexander Hein, Sherko Kümmel, R. Landthaler, Diethelm Wallwiener, Lothar Häberle, Nikos Fersis, Mahdi Rezai, B. Baier, C. Thomssen, Claudia Rauh, Christoph Mundhenke, S. Henschen, Thorsten Kühn, J.W. Siebers, S. Kellner, Tanja Fehm
Publikováno v:
Annals of Oncology. 29:186-192
Background Patients’ compliance and persistence with endocrine treatment has a significant effect on the prognosis in early breast cancer (EBC). The purpose of this analysis was to identify possible reasons for non-persistence, defined as premature
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a74a89c7fb8aa3aad2be992a0dcdf13
https://doi.org/10.1093/annonc/mdx630
https://doi.org/10.1093/annonc/mdx630
Autor:
Carolin C. Hack MD, Peter A. Fasching MD, Tanja Fehm MD, Johann de Waal MD, Mahdi Rezai MD, Bernd Baier MD, Gerold Baake MD, Hans-Christian Kolberg MD, Martin Guggenberger MD, Mathias Warm MD, Nadia Harbeck MD, Rachel Wuerstlein MD, Jörg-Uwe Deuker MD, Peter Dall MD, Barbara Richter MD, Grischa Wachsmann MD, Cosima Brucker MD, Jan W. Siebers MD, Nikos Fersis MD, Thomas Kuhn MD, Christopher Wolf MD, Hans-Walter Vollert MD, Georg-Peter Breitbach MD, Wolfgang Janni MD, Robert Landthaler MD, Andreas Kohls MD, Daniela Rezek MD, Thomas Noesslet MD, Gunnar Fischer MD, Stefan Henschen MD, Thomas Praetz MD, Volker Heyl MD, Thorsten Kühn MD, Thomas Krauss MD, Christoph Thomssen MD, Andre Hohn MD, Hans Tesch MD, Christoph Mundhenke MD, Alexander Hein MD, Claudia Rauh MD, Christian M. Bayer MD, Adib Jacob, Katja Schmidt PhD, Erik Belleville PhD, Peyman Hadji MD, Sara Y. Brucker MD, Diethelm Wallwiener MD, Sherko Kümmel MD, Matthias W. Beckmann MD, Daniela Paepke MD
Publikováno v:
Integrative Cancer Therapies
Integrative Cancer Therapies, Vol 16 (2017)
Integrative Cancer Therapies, Vol 16 (2017)
Background . Breast cancer patients often use complementary and alternative medicine, but few prospectively collected data on the topic are available specifically for postmenopausal breast cancer patients. A large prospective study was therefore cond
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::5d4228953f1d70f81af0512e555ea5b8
http://europepmc.org/articles/PMC5739129
http://europepmc.org/articles/PMC5739129
Autor:
Christian Löhberg, C Brucker, Rachel Wuerstlein, P Gaß, S. Henschen, V. Heyl, Diethelm Wallwiener, Thorsten Kühn, J.W. Siebers, Hans-Christian Kolberg, Daniela Rezek, T. Praetz, A. Hohn, A. Jacob, Nikos Fersis, Johann de Waal, G. Baake, T Noesselt, Christoph Thomssen, Thomas Krauss, M. Guggenberger, Tanja Fehm, B. Baier, Peter A. Fasching, Barbara Richter, G. Fischer, H.-W. Vollert, Christoph Mundhenke, Katja Schmidt, Mahdi Rezai, Matthias W. Beckmann, Thomas Kuhn, Christian M. Bayer, C. Wolf, A. Kohls, Claudia Rauh, Wolfgang Janni, Hans Tesch, G. P. Breitbach, Nadia Harbeck, Peter Dall, Joerg-Uwe Deuker, R. Landthaler, Sherko Kümmel, Mathias Warm, Erik Belleville, Alexander Hein, G. Wachsmann, Sara Y. Brucker, P. Hadji
Publikováno v:
Breast Care. 11:315-322
Background: Decision-making for or against neoadjuvant or adjuvant chemotherapy in postmenopausal patients with hormone receptor-positive breast cancer does not follow any clear guidelines, and some patients may unnecessarily undergo chemotherapy and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::120dfd9455f4da4141df7be53622f93b
https://doi.org/10.1159/000452468
https://doi.org/10.1159/000452468
Autor:
Nikos Fersis, Michael Friedrich
Publikováno v:
Geburtshilfe und Frauenheilkunde. 73:262-265
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ff98fb3bd6b5dea555e05d697ee80b36
https://doi.org/10.1055/s-0032-1328529
https://doi.org/10.1055/s-0032-1328529
Autor:
D. Elling, D Lampe, M Böhme, T Lantzsch, Antje Belau, Sherko Kümmel, Peter Schmid, Nikos Fersis, J Bischoff, J. Krocker, Bahriye Aktas
Publikováno v:
Cancer Research. 72:P1-14
Background: Several studies showed that pathologic complete response (pCR) is a surrogate for disease free survival (DFS) and overall survival (OS). Combinations of trastuzumab and anthracyclines in HER2-positive breast cancer are highly active but a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d6d638a5ab31678be09a7f39b6cf2fae
https://doi.org/10.1158/0008-5472.sabcs12-p1-14-05
https://doi.org/10.1158/0008-5472.sabcs12-p1-14-05
Autor:
C. Sohn, C Mayer, E. Bischofs, Thomas Bruckner, E. Anastasiou, Michael Eichbaum, Nikos Fersis
Publikováno v:
Geburtshilfe und Frauenheilkunde. 71:405-411
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7ba2ab2f0f0bd78c02a23196ba6422ac
https://doi.org/10.1055/s-0030-1271075
https://doi.org/10.1055/s-0030-1271075
Autor:
Roland Bares, Reinhard Vonthein, B. Smyczek-Gargya, Helmut Dittmann, Nikos Fersis, Rainer Kehlbach, Ajnur Jusufoska, Hans Juergen Machulla, Bernhard M. Dohmen, Maren Pritzkow
Publikováno v:
Nuclear Medicine and Biology. 36:163-169
The nucleoside analogue [(18)F]fluorothymidine (FLT) has been designed as a marker of cell proliferation that can be imaged in vivo by positron emission tomography. Clinical pilot studies have demonstrated decreasing FLT uptake following antiprolifer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a6a9c209d0285e02de421da176e9283
https://doi.org/10.1016/j.nucmedbio.2008.10.012
https://doi.org/10.1016/j.nucmedbio.2008.10.012